The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR), Université de Montréal’s drug discovery and project maturation unit based at the Institute for Research in Immunology and Cancer (IRIC), whose mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer and related fields, has entered into a strategic collaboration with AstraZeneca, a […]
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is pleased to announce that its clinical-stage spin-off company, ExCellThera, won the $20,000 first prize in the Pharma & Biotech category at the HealthKick Challenge, which took place in Toronto, Ontario, on April 5th.
ExCellThera, the result of IRICoR’s collaboration with the Centre for Commercialization of […]
Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i
Montreal, April 4, 2017 — The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and the Centre for Commercialization of Cancer Immunotherapy (C3i) are pleased to announce a major collaboration to […]
The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) of Université de Montréal will attend the 11th Annual International Partnering Conference BIO-EUROPE Spring. This conference is being held from March 20 to March 22, 2017 at the CCIB Convention Center in Barcelona, Spain.
For more information about BIO-EUROPE Spring 2017 click here : BIO-EUROPE Spring 2017
For a meeting […]
New antithrombotic drug developed through a research partnership between IRIC and Bristol-Myers Squibb
An article describing the identification and development of a new molecule to treat thrombotic diseases via a partnership with Bristol-Myers Squibb (BMS) was published in the January 4 edition of the prestigious scientific journal Science Translational Medicine.
This molecule, BMS-986120, acts on cellular receptor PAR4 involved in the activation of blood platelets in clot formation. Thus, it reduces considerably […]
Mission économique en Suisse : A real success
From January 22 to 26 2017, took place the first Mission économique en Suisse, led by Québec Chief Scientist Mr. Rémi Quirion. Ms. Nadine Beauger, Chief Executive Officer of the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) was part of a group of more than 20 representatives of the […]
A $15 million investment from Merck
Merck & Co., Inc., and the Fonds de recherche du Québec – Santé (FRQS) are proud to announce the creation of Oncopole: a research, development, and investment hub to accelerate the fight against cancer. The Oncopole is starting with a solid foundation with a $15-million financial commitment over three years from Merck. The funds will […]
Thank you for helping us fight cancer
PLEASE GIVE GENEROUSLY: all donations will go directly to cancer research.
INVITATION: Breakfast conference
Immunotherapy: When cancer cells meet serial killers (lecture given in French)
February 3, 2017, 7-8:30 am
Morris-and-Rosalind-Goodman Agora, at the Institute for Research in Immunology and Cancer
How to get to IRIC
Registration is free. Places […]
Michel Bouvier receives the Julius Axelrod Award for his contributions as a scientist and mentor
Professor Michel Bouvier, Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal (UdeM) and professor in the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine, was named recipient of the Julius Axelrod Award […]
Launch of phase II clinical trials for a molecule jointly identified by IRIC and Bristol-Myers Squibb
IRIC expands its medicinal chemistry core facility and announces the launch of phase II clinical trials for a molecule jointly identified by IRIC and Bristol-Myers Squibb
Representatives from provincial and federal governments, IRIC, IRICoR, Bristol-Myers Squibb (BMS), and life sciences sector.
Montreal, December 15, 2016 — On Wednesday, December 14, new laboratories for the medicinal core facility at the Institute for Research in […]